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ABSTRACT 
 
 
 
 
Treatment resistance is an emerging issue faced by physicians worldwide. The 
incidence of treatment resistance in schizophrenia is about 20%.Factors that may 
contribute to it include non-adherence to treatment, comorbid conditions and 
medication side effects. Clozapine, augmentation of clozapine with benzamides 
(sulpiride, amisulpride), antiepileptics (lamotrigine) and atypical antipsychotics shows 
some success in management of TRS. In extreme treatment resistance, a strategy is 
recommended that combines the proven best drug for the particular patient and 
psychosocial treatments. Treatment resistant depression is a severely disabling disorder 
which affects about 30-46% of patients with major depressive disorder. Although there 
are no proven treatment options, therapeutic strategies which include optimization of 
medications, a combination or switching of anti-depressants and an augmentation with 
non-antidepressants, psychosocial and cultural therapies and somatic therapies 
including ECT etc. are used. 
 
 
The current study was aimed at evaluating the demographic profile and management of 
treatment resistant schizophrenia and treatment resistant depression in psychiatric 
department of a tertiary care super-specialty hospital. The design of the study was 
prospective observational and a total of 52 subjects were enrolled in the study of which 
25 subjects were diagnosed with TRS and 27 were diagnosed with TRD. Treatment 
resistant cases in the hospital setting were identified by using PANSS and MADRS 
scales. We evaluate the treatment provided for those patients and monitor for 
improvement of conditions. Even though many treatment options are available, a well-
defined management guideline is not yet established. So we hope this study may 
contribute something new to the health care professionals, thereby helps improve 
patient care. From the evaluation of the demographic profile, it concluded that the 
gender doesn‟t have much influence on the occurrence of TRS. But in cases of TRD, 
females had predominance over males. Furthermore family history had a strong 
correlation with the occurrence of both TRD and TRS. 
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Clozapine is used as a gold standard in treatment of TRS. Augmentation of clozapine 
with other antipsychotics in different doses has shown clinical improvement in 
patients. Sertraline, Venlafaxine and Sodium valproate combination was majorly used 
in the treatment of TRD patients. Among them, Venlafaxine was used commonly in 
TRD. 
 
 
Adverse drug reactions are common with the use of antipsychotic drugs. There for this 
study monitor the occurrence of major adverse drug reactions in patients with TRS and 
TRD. In this study the major ADRs shown by TRS patients include weight gain, 
constipation, diabetes mellitus, extra pyramidal symptoms, sexual dysfunction and 
tachycardia and those of TRD patients include weight changes, GI problems and sexual 
dysfunction. 
 
 
The study concluded that in TRS, this specific population unresponsive to previous 
treatment, a combination of clozapine with aripiprazole, as well as other augmentation 
strategies for clozapine, seen worthy of further exploration. It also concluded that TRD 
may benefit from treatment with a more potent anti-depressant from the tricyclic anti-
depressant class or selective serotonin reuptake inhibitor or using antipsychotic 
medication or selective nor epinephrine reuptake inhibitor or mood stabilizing 
medication such as lithium may hold the key to their recovery. 
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1. INTRODUCTION 
 
 
 
Mental health (psychiatric or psychological) disorders involve disturbances in thinking, 
emotion and/or behaviour. Small disturbances in these aspects of life are common, but 
when such disturbances distress the person greatly and/or interfere with daily life, they 
are considered mental illness or a mental health disorder. The effect of mental illness 
may be long lasting or temporary. These disorders are caused by complex interactions 
between physical, psychological, social, cultural and hereditary influences. The most 
common mental disorders are obsessive compulsive disorder, posttraumatic stress 
disorder, anxiety, major depressive disorder, schizophrenia etc 
[1]. 
 
Depression is the major cause of morbidity worldwide among mental disorders 
[2]
. Of 
all the patients who are taking treatment for depression, approximately 55% of patients 
meet the criteria for treatment resistance; that is those patients failed at least 6 week 
trial of two or more classes of antidepressants. The treatment resistance occurring along 
the continuing ranging from partial response to complete refractioneries 
[3]
. 
 
Treatment-resistant depression, a complex clinical problem caused by multiple risk 
factors, is targeted by integrated therapeutic strategies, which include optimization of 
medications, a combination of antidepressants, switching of antidepressants, and 
augmentation with non-antidepressants, psychosocial and cultural therapies, and 
somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic 
stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct 
current stimulation, and vagus nerve stimulation 
[3]
. 
 
Schizophrenia, another commonly occurring mental illness, which is a chronic thought 
disorder in which characteristic psychiatric symptoms are seen during the acute phase 
of illness with partial or full resolution of symptoms between psychiatric episodes 
coupled with deterioration from the previous level of social or occupational functioning 
[4]
. The impact of schizophrenia tends to be highest in Oceania, the Middle East and 
East Africa, while the nations of Australia, Japan, US and most Europe typically have 
low impact. A schizophrenic patient can be termed as resistant to treatment only after 
an inadequate response to trial of any two second generation antipsychotics or one first 
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generation and one second generation antipsychotics for duration of 4 to 10 weeks 
[5]
.The treatment resistance is as high as 15% even in first episode of schizophrenic 
patient. It is one of the most important clinical challenges in the pharmacological 
management of schizophrenia. Therefore the evaluation of the therapeutic options in 
case of treatment resistance is highly clinically relevant 
[6]
. Treatment of TRS includes 
management with clozapine, atypical antipsychotics (risperidone, olanzapine, 
quetiapine, and amisulpiride), augmentation with antidepressants (fluoxetine, 
paroxetine, and fluvoxamine), mood stabilizers (valproate, carbamazepine, 
lamotrigine). Also electro convulsive therapy (ECT) has been used in combination with 
clozapine and has been found to be safe and clinically beneficial 
[7]
. 
 
1.1 SIGNS AND SYMPTOMS 
 
 
1.1.1 DEPRESSION 
 
Five or more of the following symptoms present nearly every day for 2 weeks. 
 Depressed mood most of every days.
 Marked decreased interest or pleasure in most all activities (anhedonia).
 Appetite or weight change (5% body weight in 1 month).
 Insomnia or hypersomnia.
 Psychomotor agitation or retardation.
 Fatigue or loss of energy.
 Worthlessness, excessive guilt.
 Decreased ability to think or concentrate indecisiveness.
 Recurrent thoughts of death, suicidal ideation or attempt [2].
 
 
1.1.2 SCHIZOPHRENIA 
 
Either at least one of the syndromes, symptoms and signs listed below under (1), or at 
least two of the symptoms and signs listed under (2), should be present for most of the 
time during an episode of psychotic illness lasting for at least one month (or at some 
time during most of the days). 
 
 
(1) At least one of the following: 
 
a) Thought echo, thought insertion or withdrawal, or thought broadcasting. 
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b) Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions, or sensations; delusional perception. 
 
c) Hallucinatory voices giving a running commentary on the patient's behaviour, or 
discussing him between themselves, or other types of hallucinatory voices coming 
from some part of the body. 
 
d) Persistent delusions of other kinds that is culturally inappropriate and completely 
impossible (e.g. being able to control the weather, or being in communication with 
aliens from another world). 
 
 
(2) or at least two of the following: 
 
a) Persistent hallucinations in any modality, when occurring every day for at least one 
month, when accompanied by delusions (which may be fleeting or half-formed) 
without clear affective content, or when accompanied by persistent over-valued 
ideas. 
 
b) Neologisms, breaks or interpolations in the train of thought, resulting in 
incoherence or irrelevant speech. 
 
c) Catatonic behaviour, such as excitement, posturing or waxy flexibility, negativism, 
mutism and stupor. 
 
d) "Negative" symptoms such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses (it must be clear that these are not due to 
depression or to neuroleptic medication) 
[8]
. 
 
1.2 ASSESMENT OF SEVERITY OF SYMPTOMS 
 
In this study MADRS is used to assess depression and PANSS is used to assess the 
severity of symptoms of schizophrenia .Based on the individual scoring of patients, 
whether the patient is treatment resistant or not is defined. 
 
 
1.2.1 Montgomery–Asberg Depression Rating Scale (MADRS) 
 
The clinician-rated Montgomery and Asberg Depression Rating Scale (MADRS) was 
developed in the late 1979 by British and Swedish researchers as an adjunct to the 
Hamilton Rating Scale for Depression (HAMD) and this 10-item scale was designed to 
be sensitive to the effects of antidepressant medications, primarily tricyclic 
antidepressants (TCAs).Because this scale was Rating Scales for Depression never 
updated or modified, it does not target reverse neurovegetative symptoms. It is 
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commonly used in clinical studies and in clinical practice, administered weekly. 
Structured interview guides for the MADRS have been developed by a number of 
investigators of Reliability Internal Consistency. The MADRS appears to be a one 
dimensional scale, more focused toward psychological, as opposed to somatic aspects 
of depression. The internal consistency of the MADRS is considered very high, given 
the high correlation between all items (r = 0.95). 
 
 
In a recent psychometric re-analysis of primary efficacy measures derived from a trial 
on citalopram efficacy in maintenance therapy of elderly depressed patients, the 
internal consistency of the MADRS, was found to be more superior to that of the 
HAM-D- 17. Inter-rater Reliability One of the original goals of the MADRS was to 
obtain an instrument that could be used by both psychiatrists and professionals without 
a specific or with minimal psychiatric training. From the original report of the 
MADRS, the inter-rater reliability ranged from 0.89 to 0.97. However, in a German 
study, significant differences resulted when the same patient was rated by various 
groups of caregivers (psychiatrists, psychologists, students, and psychiatric nurses). 
Validity Correlation of MADRS has been shown to be generally high or very high with 
the HAM-D (between 0.80 and 0.90), RDC (0.70), and with IDS-C (0.81) .Cut-Off 
Scores A score greater than 30 or 35 on the MADRS indicates severe depression, while 
the score of 10 or below indicates remission. Zung Self-Report Depression Scale 
[9]
. 
 
1.2.2 POSITIVE AND NEGETIVE SYNDROME SCALE (PANSS) 
 
One of the most widely used measures of psychopathology of schizophrenia in clinical 
research is the Positive and Negative Syndrome Scale (PANSS). The 30- item PANSS 
was developed originally for typological and dimensional assessment of patients with 
schizophrenia and was conceived as an operational zed, change-sensitive instrument 
that offers balanced representation of positive and negative symptoms and estimates 
their relationship to one another and to global psychopathology by Stanley Kay, Lewis 
Opler, and Abraham Fiszbein in 1987. It consists of three subscales measuring the 
severity of Positive Symptoms (seven items), severity of Negative Symptoms (seven 
items), and General Psychopathology (16 items). 
 
 
The PANSS is typically administered by trained clinicians who evaluate patients‟ 
current severity level on each item by rating one of seven options (scores) representing 
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increasing levels of severity. The administration generally takes 30 to 60 minutes, 
depending on the patient‟s level of cooperation and severity of symptoms. The PANSS 
has demonstrated high internal reliability, good construct validity, and excellent 
sensitivity to change in both short term and long term trials. However, despite 
extensive psychometric research on the PANSS, until a recent Item Response Analysis 
(IRT) it was unclear how individual PANSS items differ in their usefulness in assessing 
the total severity of symptoms. All 30 items of this scale are rated on a 7-point scale (1 
= absent; 7 = extreme). There are 3 subscales of the PANSS, the Positive Symptom 
subscale, the Negative Symptom subscale and the General Psychopathology subscale. 
The PANSS was developed with a comprehensive anchor system to improve the 
reliability of ratings. The 30 items are arranged as seven Positive subscale items (P1 - 
P7), seven Negative subscale items (N1 - N7), and 16 General Psychopathology items 
(G1 - G16). Each item has a definition and a basis for rating. 
 
 
The interviewer must be trained to a standardized level of reliability for conducting the 
interview. PANSS rater, was required to obtain rater certification through Ortho-
McNeil Janssen Pharmaceuticals, Incorporated, and to achieve interpreter reliability 
with an interclass correlation coefficient (95% CI) = 0.80 with the “Expert consensus 
PANSS” scores 
[10]
. 
 
1.2.2.1 SCORING 
 
As 1 rather than 0 is given as the lowest score for each item, a patient cannot score 
lower than 30 for the total PANSS score. Scores are often given separately for the 
positive items, negative items, and general psychopathology. In their original 
publication on the PANSS scale, Stanley Kay and colleagues tested the scale on 101 
patients with schizophrenia and the mean scores were, 
 Positive scale = 18.20
 Negative scale = 21.01
 General psychopathology = 37.74 [10]
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1.3 MANAGEMENT 
 
 
1.3.1 MANAGEMENT OF TRD 
 
Treatment-resistant depression, a complex clinical problem caused by multiple risk 
factors, is targeted by integrated therapeutic strategies, which include optimization of 
medications, a combination of antidepressants, switching of antidepressants, and 
augmentation with non-antidepressants, psychosocial and cultural therapies, and 
somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic 
stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct 
current stimulation, and vagus nerve stimulation. As a corollary, more than a third of 
patients with treatment-resistant depression tend to achieve remission and the rest 
continue to suffer from residual symptoms. The latter group of patients needs further 
study to identify the most effective therapeutic modalities. Newer biomarker-based 
antidepressants and other drugs, together with non-drug strategies, are on the horizon to 
address further the multiple complex issues of treatment-resistant depression 
[11]
. 
 
1.3.1.1 APPROACH TO PATIENTS WITH TREATMENTRESISTANT 
 
DEPRESSION 
 
Patient with depression fails to respond to at least 8 weeks of antidepressant therapy at 
 
an adequate dosage.  
 
 
 
 
 
 
Confirm diagnosis. 
 
Confirm medication adherence. Consider serum blood levels (primarily for TCAs).  
 
 
 
 
 
 
Rule out organic causes of depression. 
 
Maximize treatment of complicating co morbid diagnoses  
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Switch to another antidepressant or augment current medication with CBT, Bupropion, 
or buspirone. Consider psychiatric consultation. 
 
 
 
 
 
 
 
Switch to a different pharmacologic class of antidepressant (e.g., TCA, mirtazapine), or 
augment current medication with lithium or triiodothyronine. 
 
 
 
 
 
 
 
Switch to tranylcypromine or extended release venlafaxine plus mirtazapine. Seek 
psychiatric consultation. Consider ECT. 
 
 
{Algorithm for management of treatment resistant depression (CBT = cognitive 
behaviour therapy; ECT = electroconvulsive therapy; TCA = tricyclic 
antidepressant.)}
[12]
. 
 
1.3.1.2 Optimization of antidepressants 
 
The two core features of this strategy are to optimize dosage and duration of 
antidepressant therapy for patients who have experienced only partial improvement. 
The advantages of this strategy are to capitalize on the natural history of episodic 
depression which remits over time and to counteract the tendency of some patients to 
discontinue the antidepressant prematurely 
[13]
. 
 
1.3.1.3 Switching strategies 
 
The switching approach mainly involves discontinuing an ineffective antidepressant 
and starting a new antidepressant from a similar or different class in patients with 
treatment resistant depression. The advantages of this strategy are improved adherence, 
reduced medication costs and fewer drug interactions 
[14]
. 
 
1.3.1.4 Combination of antidepressants 
 
Combination therapy involves the addition of a second antidepressant agent from a 
different class to the therapeutic regimen of patients with treatment-resistant 
depression. The additional antidepressant is used for 12 weeks or even months in 
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optimum doses. Various types of combination are reported in the literature, but the 
most common are TCA + SSRI followed by, e.g., venlafaxine + TCA, SSRI + SSRI, 
and SSRI + venlafaxine. Venlafaxine +mirtazapine are frequently used in clinical 
practice, and this combination produces a good response in patients with difficult-to-
treat depression, which is attributed to the synergistic action of this combination 
[15]
. 
 
1.3.1.5 Augmentation strategies 
 
Augmentation therapy involves adding a second agent (but one that is not routinely 
regarded as an antidepressant) to the therapeutic regimen when there is only a partial 
response to the primary antidepressant agent. The reported strength of recommendation 
for augmentation or switching is best supporting evidence. Various augmenting agents, 
including lithium, atypical antipsychotics, thyroid hormone, pindolol, buspirone, 
dopamine agonists, sex steroids, glucocorticoid-specific agents, herbal products, and 
newer anticonvulsants, have been used in patients with treatment-resistant depression 
[16]. 
 
 
1.3.1.6 Electroconvulsive therapy 
 
ECT is a recognized mode of treatment for a variety of mental disorders, including 
treatment resistant depression. ECT is still the most consistently effective in patients 
with treatment resistant depression, with a response rate of 50%–70%.30[21]. 
Furthermore, ECT remains the treatment of first choice for the most severe, 
incapacitating forms of treatment resistant depression, though the strength of the 
recommendation of ECT is level C[20].Surprisingly, relapse rates are significantly 
higher in patients with treatment resistant depression after a successful course of 
therapy 
[17]
. 
 
1.3.1.7 Other somatic therapies 
 
These reversible but more invasive therapies were developed to avoid the adverse 
effects and complications of ECT and at the same time to be more effective in 
treatment resistant depression. rTMS and VNS are approved by the US Food and Drug 
Administration for the treatment of intractable seizure disorders and treatment-resistant 
depression. However, with regard to treatment resistant depression, other 
neuromodulation therapies, including DBS, magnetic seizure therapy, and tDCS, are in 
the experimental stages 
[18]
. 
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1.3.1.8 Psychotherapy 
 
A variety of psychotherapeutic techniques can be used to treat depression, including 
CBT, interpersonal psychotherapy, nondirective counselling, befriending, problem 
solving therapy, psychodynamic psychotherapy, group psycho education, cognitive 
behavior analysis and also exercise 
[19]
. However, evidence regarding the effectiveness 
of psychotherapeutic techniques in patients with treatment resistant depression is 
limited. 
 
 
In summary, 70% of patients with major depression respond to initial antidepressant 
therapy, leaving 30% of patients who are refractory to treatment and therefore need 
special treatment-resistant depression management strategies. Twenty-five percent of 
patients with treatment-resistant depression tend to respond to optimization and 
combined treatment paradigms and another 50% of patients are reported to respond to 
switching therapeutic options. Augmentation strategies target the remaining 25% of 
patients suffering from treatment-resistant depression, with inconsistent outcomes. 
Overall, although there is no strict compartmentalization of treatment response and 
remission rate in the population with treatment-resistant depression, about one third of 
patients with the disorder continue to be resistant to available therapeutic options, and 
hence pose a major therapeutic challenge to mental health experts 
[11]
. 
 
1.3.2 MANAGEMENT OF TRS 
 
The goals and strategies of treating a patient with schizophrenia vary according to the 
phase and severity of illness. In the acute phase, the goal is to reduce or eliminate 
psychotic symptoms and improve functioning. During stabilization, the goal is to 
provide support to decrease the risk of relapse, increase the patient‟s adaptation to life 
in the community, and consolidate remission of symptoms. In the stable phase, the goal 
is to ensure that the patient maintains and improves his or her level of functioning and 
quality of life, and to treat any re-emerging psychotic symptoms, while adverse-effect 
monitoring and management continues. Second-generation antipsychotics (SGAs) 
(with the exception of clozapine) have become the agents of first choice in the 
treatment of schizophrenia, and most practice guidelines and consensus statements 
support this recommendation. The major advantage of atypical antipsychotics may be 
in their side effect profiles with respect to motor effects, as they generally have better 
overall tolerability than the FGAs 
[20]
. 
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Risperidone fulfils the atypical criterion of having a low incidence of EPS at low to 
moderate doses. The mean optimal dose in parallel, fixed-dose studies was 4 to 6 mg 
daily. At doses greater than6mg daily, risperidone‟s profile is more similar to that of an 
FGA. Because risperidone appears to lose its atypical profile at higher doses, the 
lowest possible dose should be used in treatment. This may include gradual dose 
titration downward if patients do not respond initially, rather than upward titration as 
has been the traditional approach to dosing antipsychotics 
[21-23]
. 
 
Olanzapine has a very low incidence of EPS when used within the approved dose range 
of 10 to 20 mg daily. However, many patients are being treated at doses above the 
currently recommended limit in the approved product labelling of 20 mg/day. 
Quetiapine is an efficacious antipsychotic with an excellent EPS profile. Although 
contrary to efficacy studies, doses above 500 mg are often used to achieve optimal 
effects, with dose titration to 800 mg/day being a common occurrence. From a clinical 
perspective, the optimal daily quetiapine dose appears unclear 
[24]
. 
 
Ziprasidone 40 to 160 mg/day appears to have efficacy similar to other SGAs, with 
response rates increasing at doses greater than 80 mg daily. Aripiprazole has 
established efficacy at 15 to 30 mg/day. Both aripiprazole and ziprasidone have 
significantly less potential to produce weight gain than other SGAs 
[25]
 . 
 
The first is inadequate duration of treatment. It is accepted that a proportion of patients 
have a delayed response to clozapine (Meltzer, 1992). Meltzer concluded that 30% 
would respond by 6 weeks, a further 20% by 3 months and an additional 10–20% by 6 
months. Therefore, it seems reasonable to try clozapine monotherapy for 6 months. 
This leaves a residue of 30% of patients for whom it must be decided whether to 
persevere with clozapine 
[26]
. 
 
The second factor is inadequate dosage. Clozapine dosage can be a relatively 
complicated issue. In particular, there is no meaningful relationship between clozapine 
plasma levels and clinical response. However, there is a consensus in the literature that 
a plasma level of about 350–450ng/ ml has to be attained before the patient is 
considered to be non-respondent to clozapine (Perry et al, 1991; Patient al, 1994).[26] 
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Clozapine is also subject to considerable metabolism by the cytochrome P450 (CYP) 
enzyme system (Aitchison et al, 2000). There are numerous variants of the genes 
encoding the CYP enzyme family within the general population, resulting in complex 
individual genetic profiles and a variable response to drugs metabolized by these 
enzymes (Ma et al, 2004). † Therefore, in clinical practice, patients can be very 
susceptible to side-effects at drug dose levels that appear to be below the threshold for 
clinical efficacy 
[26]
. 
 
1.3.2.1 Pharmacotherapy of Treatment Resistance Schizophrenia – Algorithm 
 
 
 
 
Clinical scenario: No adequate response to an initial trial with antipsychotics.  
 
 
 
 
 
 
 
 
Before assuming non response, the following issues should be checked. 
 
 Is the underlying diagnosis of a schizophrenic disorder correct?
 Are there relevant co morbidities?
 Is there a possible non-compliance in terms of medication intake?
 Was a sufficient dose of the antipsychotic achieved?
 Was the duration of the treatment sufficiently long?(at least 2-4 weeks at the 
target dose)

 Were sufficient plasma level achieved?
 Do adverse effects mask a response? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
Padmavathi College Of Pharmacy 
 
High dose treatment or switch off the antipsychotic drug  
 
 
 
 
High dose treatment 
 
In a randomized clinical trials, there was 
no superiority of high dose medication 
(e.g. deficient as higher than the label 
dose) in comparison to administration of a 
standard dose for the majority of patients. 
 
 
 
 
Switch off antipsychotics 
 
In studies with control group, the superiority 
of switching strategies was rather low overall, 
however there is slightly more evidence for a 
switch off the antipsychotics drug than for a 
high dose treatment based on studies without 
a control group. Drugs should be switched 
preferentially to an antipsychotic with a 
different receptor binding profile. 
 
 
 
 
 
 
 
 
 
 
 
Medication with Clozapine 
 
 
 Should be considered after non response to at least two trials with antipsychotic 
agents minimum treatment duration: eight weeks, plasma level guided

 
 
 
 
 
 
 
Combination and augmentation strategies 
 
 
 Currently there is no sufficient convincing evidence to recommend such 
strategies, generally an antipsychotic monotherapy should be sough primarily.


 Utilization preferably for treating specific target symptoms (eg: 
Benzodiazepines for agitated patients or antidepressant affective symptoms.


 For combination treatment two antipsychotics with a different receptor binding 
profile should be chosen.

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In the clinical practice of today, treatment-resistance cannot be categorically evaluated 
according to response, or lack thereof, to drug treatment. Setting forth Andresen‟s ideas 
on the concept of remission, we are closer to operational dimensional models that 
integrate the idea of continuum, and we speak of a lack of sufficient response. We 
believe that this concept should be more inclusive in its current vision of treatment 
resistant schizophrenia, since it could contribute a notion of continuum with response 
levels up to recovery of premorbid functioning, with regard to the individual‟s life 
expectations. Furthermore, it takes up the ideas of Brenner et al and Meltzer by 
integrating different pharmacological approaches, without denying the importance of 
drugs, while hoping for advances in research on pro-cognitive compounds, 
antipsychotic drugs, etc., which will mark new therapeutic milestones. 
 
 
1.4 STUDY OF ADVERSE DRUG REACTIONS. 
 
All drugs with the ability to produce a desired therapeutic effect also have the potential 
to cause unwanted adverse effects. The WHO defines ADR as „A response to a drug 
that is noxious, unintended and occurs at doses normally used in man for prophylaxis, 
diagnosis or therapy of diseases or for modification of physiological function. 
 
 
1.4.1 TYPES OF ADR 
 
According to Rawlings Thomson system, ADR is classified in to different types as, 
 
1. Type A: They are normal but quantitatively exaggerated pharmacological effect of 
the drug. 
 
2. Type B: They are qualitatively abnormal effects which appear unrelated to the drugs 
pharmacology. 
 
3. Type C: They occur with continuous use of certain drugs, which is related to the 
cumulative dose of the drug and are rarely occurring. 
 
4. Type D: This reaction occurs usually within a short period after the stoppage of the 
drug. 
 
5. Type E: They occur soon after the withdrawal of the drug. 
 
6. Type F: These are very common and dose related, occurs due to inappropriate use of 
drugs or due to treatment failure. 
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The common ADRs shown by antipsychotics and antidepressants are extra pyramidal 
symptoms, metabolic syndrome, inappropriate prolactin level, sexual problems etc. 
 
 
Naranjo scale and WHO causality assessment scales are mainly used to evaluate the 
ADR. 
 
 
1.4.2 NARRANJO SCALE 
 
The Naranjo algorithm, Naranjo Scale, or Naranjo Nomo gram is a questionnaire 
designed by Naranjo et al. for determining the likelihood of whether an ADR (adverse 
drug reaction) is actually due to the drug rather than the result of other factors. 
Probability is assigned via a score termed definite, probable, possible or doubtful. 
Values obtained from this algorithm are sometimes used in peer reviews to verify the 
validity of author's conclusions regarding adverse drug reactions. It is also called the 
Naranjo Scale or Naranjo Score. 
 
. 
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 2. AIM & OBJECTIVES 
 
 
 
 
 
2.1 Aim: 
 
 
 
To evaluate the demographic profile and management of treatment resistant 
schizophrenia and treatment resistant depression in psychiatric department. 
 
 
 
 
2.2 Objectives: 
 
 
1. To evaluate the demographic profile of TRS and TRD in psychiatric patients. 
 
2. To assess the treatment modalities in managing TRS and TRD patients. 
 
3. To monitor the adverse drug events associated with drug therapy. 
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2.3 Plan of study  
 
 
Selection of project title  
 
 
 
 
Conduct of literature review  
 
 
 
 
Framing of protocol for study  
 
 
 
 
Obtaining ethical committee approval  
 
 
 
 
Data collection  
 
 
 
 
Statistical analysis  
 
 
 
 
Formulation of results and interpretation 
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3. REVIEW OF LITERATURE 
 
 
 
 
 
3.1 The Combined Treatment of Venlafaxine and Quetiapine for Treatment-
Resistant Depression: A Clinical Study 
 
Xiaoyi Li, M.D. et al (2013) conducted a randomized control trial on TRD patients and 
studied the efficacy and safety of combined venlafaxine and quetiapine treatment for 
treatment-resistant depression (TRD) by dividing 95 TRD patients into two treatment 
groups: a combined venlafaxine (225 mg/day) and quetiapine (400mg/day) group and a 
venlafaxine only (225 mg/day) group for 8 weeks. Efficacy was assessed with the 
Hamilton Rating Scale for Depression, 17 items (Ham-D–17) and the Hamilton Rating 
Scale for Anxiety (Ham-A); safety was assessed with the Treatment-Emergent 
Symptom Scale (TESS). All data were represented as means (standard deviations [SD]) 
and analyzed with SPSS 12.0 software (Chicago, IL, U.S.). x
2
 and t-tests were applied, 
and ∞ <0.05 was considered to be statistically significant in all cases. The two groups 
showed significant differences for the Ham-D–17 and Ham-A and no differences on the 
TESS. The present study showed that a combined treatment of venlafaxine and 
quetiapine provided benefits for TRD patients beyond those seen with venlafaxine 
alone. Also, a target venlafaxine dose of 225 mg/day was safe for patients in 
combination with quetiapine at a dose of 400 mg/day. 
 
 
3.2 Role of Amisulpiride Augmentation in Treatment Resistant Major Depressive 
Disorder: An Open Label Study from North India 
 
Mansoor Ahmad Dar et al (2015) evaluated whether augmentation with amisulpride 
was effective and tolerable in patients of major depressive disorder (MDD) who did not 
respond significantly to adequate trials of standard antidepressants. In this open labeled 
6 weeks study, amisulpride was added to baseline antidepressant medication of 
treatment resistant patients of major depressive disorder. A total of 112 patients 
enrolled in the study with a mean age of 39.37 years out of which 83% completed the 
study. Over a period of 6 weeks, 71% patient showed response and 40% patient 
remitted (p<0.001) with a mean amisulpride dose of 135.31 mg/day. The mean 
decrease in HAM-D17 score was 16.17 points. There was more than 2 point change in 
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mean CGI-S score from base line to endpoint. Common adverse effects were akathisia 
(4.64%), sleep disturbances (10.71%), restlessness (5.36%) and extra pyramidal side-
effects (4.64%). The study concluded that augmentation of antidepressant drugs with 
low doses of amisulpride seemed to be effective and tolerable in patients of major 
depressive disorder who do not respond adequately to standard antidepressant 
medications. 
 
 
3.3 Treatment-Resistant Depression: Therapeutic Trends, Challenges, and Future 
Directions 
 
Khalid Saad Al-Harbi et al (2012) in a meta-analysis reviewed the therapeutic options 
for treating resistant major depressive disorder, as well as evaluated further therapeutic 
options. Those papers that directly addressed treatment options for treatment-resistant 
depression were extensively reviewed. This study described treatment-resistant 
depression, a complex clinical problem caused by multiple risk factors, was targeted by 
integrated therapeutic strategies, which include optimization of medications, a 
combination of antidepressants, switching of antidepressants, and augmentation with 
non-antidepressants, psychosocial and cultural therapies, and somatic therapies 
including electroconvulsive therapy, repetitive transcranial magnetic stimulation, 
magnetic seizure therapy, deep brain stimulation, transcranial direct current 
stimulation, and vagus nerve stimulation. It concluded that newer biomarker-based 
antidepressants and other drugs, together with non-drug strategies, are on the horizon to 
address further the multiple complex issues of treatment-resistant depression and 
treatment-resistant depression continues to challenge mental health care providers, and 
further relevant research involving newer drugs is warranted to improve the quality of 
life of patients with the disorder. 
 
 
3.4 Effects of Risperidone Augmentation in Patients with Treatment-Resistant 
Depression: Results of Open-Label Treatment Followed by Double-Blind 
Continuation 
 
Mark Hyman Rapaport et al (2006) investigated the longer-term efficacy of 
risperidone augmentation of serotonin-selective reuptake inhibitor treatment for 
resistant depression. In 57 in- and outpatient centers in three countries, they conducted 
a three-phase study with 4–6 weeks of open-label citalopram monotherapy, 4–6 weeks 
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of open-label risperidone augmentation, and a 24-week double-blind, placebo-
controlled discontinuation phase. A total of 489 patients with major depressive disorder 
and 1–3 documented treatment failures entered the citalopram monotherapy phase (20– 
60 mg/day). Patients with <50% reduction in HAM-D-17 scores entered the risperidone 
augmentation phase (0.25–2.0 mg/day). Patients with HAM-D-17 ≤ 7 or CGIS ≤ 2 
were randomized to risperidone or placebo augmentation. The primary outcome was 
time to relapse during the double-blind phase. During citalopram monotherapy, 434 
patients had <50% HAM-D-17 reduction; 299 (68.9%) were fully nonresponsive 
(<25% reduction) and 135 were partially nonresponsive (25–49% reduction). Of the 
386 nonresponders who entered the augmentation phase, 243 remitted and 241 entered 
the double-blind phase. Median time to relapse was 102 days with risperidone 
augmentation and 85 days with placebo (NS); relapse rates were 53.3 and 54.6%, 
respectively. In a post hoc analysis of patients fully nonresponsive to citalopram 
monotherapy, median time to relapse was 97 days with risperidone augmentation and 
56 with placebo (p =0.05); relapse rates were 56.1 and 64.1%, respectively (p ≤ 0.05). 
This large international multicenter study demonstrated that risperidone augmentation 
of citalopram was a reasonable and safe strategy that was helpful for some patients with 
treatment-resistant major depressive disorder. 
 
 
3.5 Advances in the Management of Treatment-Resistant Depression 
 
Paul E. Holtzheimer (2010) in this article defined and discussed the epidemiology of 
TRD, reviewed the current approaches to its management, and then provided an 
overview of several developing interventions. Papers that directly addressed treatment 
resistant depression were analyzed. In this study they concluded that advances in the 
management of TRD included the development of a number of novel pharmacological 
agents, many of which target systems outside the monoamines, as well as several focal 
neuromodulation techniques and overall, there is optimism that these strategies will 
lead to antidepressant treatments to help achieve and sustain remission in a greater 
number of depressed patients. The study stated that progress to date has been limited: 
despite encouraging preliminary results, none of the novel drugs are yet established for 
clinical use; the two FDA-approved brain stimulation therapies (VNS and TMS) are 
associated with relatively low response and remission rates, and neither has shown 
efficacy in those patients with the most extreme forms of treatment-resistant depression 
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(i.e., more than six treatment failures in the current episode); and data on the remaining 
brain stimulation approaches are far too preliminary to draw meaningful conclusions 
regarding safety and efficacy. 
 
 
3.6 Pharmacologic Approaches to Treatment Resistant Depression: A Re-
examination for the Modern Era 
 
Noah S. Philip et al (2010) in this review surveyed literature on the diagnosis and 
pharmacological management of TRD in light of recent developments. Evidence 
regarding commonly used treatment options is critically examined and key 
recommendations are offered. The review ends by considering drugs acting on the 
melatonin, acetylcholine, and glutamate systems that hold promise as future options for 
TRD. This review says that currently available treatments have limited efficacy for 
TRD, a state of affairs that is complicated by a lack of consensus on the definition of 
TRD itself and although there is no clear “magic bullet” to address TRD, there are a 
wide variety of pharmacological options available with established, even if modest, 
efficacy. This articles explains several novel therapeutic options, targeting 
neurotransmitter systems outside of the standard monoamine hypothesis that are 
currently being investigated as promising alternatives. This review suggest that 
increasing recognition of the role of inflammation in depression, one can also hope that 
agents affecting these processes may prove to have utility for TRD. Ultimately they opt 
better understanding of the basic pathophysiology of TRD that will be needed to 
develop better-targeted and more effective treatments. 
 
 
3.7 Cognitive and Psychosocial Improvements Following Aripiprazole 
Augmentation of SSRI Antidepressant Therapy in Treatment Refractory 
Depression: A Pilot Study 
 
Tracy L. Greer et al (2013) with this study evaluated depressive symptom severity, 
cognitive function, and psychosocial function before and after six weeks of open-label 
aripiprazole augmentation treatment in patients with MDD who did not fully respond to 
selective serotonin reuptake inhibitor treatment. Participants endorsed difficulty with 
concentration and decision-making at study entry. Participants were maintained on 
their entry-level dose of SSRI and a flexible dose of 5 mg to 15 mg aripiprazole was 
added to their SSRI for 6 weeks. Participants started at 5 mg and went up to 15 mg 
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only if clinically indicated and not contraindicated due to adverse effects. Participants 
were assessed for possible abnormal involuntary movements or extrapyramidal 
symptoms at every visit. The primary aim of the study was to determine the effect of 
aripiprazole augmentation on depressive symptom severity, psychosocial function and 
cognitive function. Changes in depressive symptom severity and psychosocial function 
were assessed via t-tests. The results of this study support significant functional 
improvements, in addition to significant reductions in depressive symptoms, in quality 
of life, psychosocial function, and executive functioning following aripiprazole 
augmentation in MDD. In addition, aripiprazole augmentation was generally well-
tolerated. 
 
 
3.8 Atypical Antipsychotic Augmentation for Treatment- Resistant Depression: A 
Systematic Review and Network Meta-Analysis 
 
Xinyu Zhou et al (2015) performed a network meta-analysis, which integrates direct 
and indirect evidence from randomized controlled trials (RCTs), to investigate the 
comparative efficacy and tolerability of adjunctive atypical antipsychotics for 
treatment-resistant depression (TRD). Systematic searches resulted in 18 RCTs (total n 
 
= 4422) of seven different types and different dosages of atypical antipsychotics and a 
placebo that were included in the review. The review observed that all standard-dose 
atypical antipsychotics were significantly more efficacious than placebo in the efficacy 
(standardized mean differences [SMDs] ranged from -0.27 to -0.43). There were no 
significant differences between these drugs. Low-dose atypical antipsychotics were not 
significantly more efficacious than the placebo. In terms of tolerability, all standard-
dose atypical antipsychotics, apart from risperidone, had significantly more side-effect 
discontinuations than placebo (odds ratios [ORs] ranged from 2.72 to 6.40). In terms of 
acceptability, only quetiapine (mean 250–350 mg daily) had significantly more all-
cause discontinuation than placebo (OR = 1.89). In terms of quality of life/functioning, 
standard dose risperidone and standard-dose aripiprazole were more beneficial than 
placebo (SMD = -0.38; SMD = -0.26, respectively), and standard-dose risperidone was 
superior to quetiapine (mean 250–350 mg daily). Study concluded that all standard-
dose atypical antipsychotics for the adjunctive treatment of TRD are efficacious in 
reducing depressive symptoms. Risperidone and aripiprazole also showed benefits in 
improving the quality of life of patients. 
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3.9 Treatment-Resistant Depression in Primary Care across Canada 
 
Sakina J Rizvi et al (2014) conducted a study to investigate the prevalence of TRD 
and to evaluate its clinical characterization and management, compared with non-
resistant depression, in primary care centres. They completed a case report on a 
consecutive series of patients with major depressive disorder (n = 1212), which 
captured patient demographics and comorbidity, as well as current and past medication. 
The result showed that using failure to respond to at least 2 antidepressants (ADs) from 
different classes as the definition of TRD, the overall prevalence was 21.7%. There 
were no differences in prevalence between men and women or among ethnicities. 
Patients with TRD had longer episode duration, were more likely to receive 
polypharmacy (for example, psychotropic, lipid-lowering, and antiinflammatory 
agents), and reported more AD related side effects. Higher rates of disability and 
comorbidity (axes I to III) were associated with treatment resistance. Obesity and being 
overweight were also associated with treatment resistance. In summary, they concluded 
that TRD is prevalent, posing a significant issue, owing to its association with 
functional and symptom burden and the management of patients within a primary care 
sample from across Canada mostly followed clinical guidelines regarding AD choice, 
duration, and treatment strategies. 
 
 
3.10 Somatic Therapies for Treatment Resistant Depression: ECT, TMS, VNS, 
DBS 
 
Cristina Cusin et al (2012) reviewed the literature for articles reporting results for 
clinical trials in particular efficacy data, contraindications and side effects of somatic 
therapies including electroconvulsive therapy (ECT), transcranial magnetic stimulation 
(TMS), vagal nerve stimulation (VNS) and deep brain stimulation (DBS). A literature 
search was performed using PubMed, Ovid Medline, Cochrane Database of Systematic 
Reviews and PsychINFO for articles published between 1990 and July 2011. The aim 
of this paper was to review new somatic therapies utilized in the treatment of TRD in 
comparison with electroconvulsive therapy (ECT), considered the “gold standard” for 
patients with TRD. The study showed that each of these devices has an indication for 
patients with different level of treatment resistance, based on acuteness of illness, 
likelihood of response, costs and associated risks. ECT is widely available and its 
effects are relatively rapid in severe TRD, but its cognitive adverse effects may be 
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cumbersome. TMS is safe and well tolerated, and it has been approved by FDA for 
adults who have failed to respond to one antidepressant, but its use in TRD is still 
controversial as it is not supported by rigorous double-blind randomized clinical trials. 
The options requiring surgical approach are VNS and DBS. They concluded that each 
method have its own advantages and side effects for the patients and need further 
studies. 
 
 
 
 
3.11 Augmentation Treatments with Second-generation Antipsychotics to 
Antidepressants in Treatment-resistant Depression 
 
Masaki Kato et al (2013) reviewed the efficacy and tolerability of SGA augmentation 
when added to antidepressant therapy for treatment-resistant MDD patients in acute 
phase studies published to date. They studied meta-analysis and randomized control 
trial of various authors on “Second-generation Antipsychotic Augmentation in 
Treatment-resistant Depression”. They concluded based on clinically evaluated 
evidence that, SGAs may act as a successful adjunctive medical agent for patients who 
fail to respond to pharmacological monotherapy with antidepressants. The SGAs 
evaluated in this review, including aripiprazole, olanzapine, quetiapine and risperidone, 
have varying degrees of efficacy in TRD patients and account for approximately a -3-
point difference on rating scales for depression and approximately a 10 % 
improvement in remission rate compared with placebo augmentation, although there is 
no clear evidence to recommend one over the others. They concluded that each SGA 
has particular adverse properties that could be severe, leading patients to 
discontinuation from the treatment or could be mild with fewer risks of 
discontinuation. The review suggest risk and benefit assessment when clinicians are 
considering subsequent pharmacotherapy following failed treatment with 
antidepressants. 
 
 
3.12 Pharmacological Management of Treatment Resistant Depression: A Clinical 
Review 
 
Noel Kennedy et al (2003) in this paper reviewed evidence for pharmacological 
approaches used in treatment resistant depression. Electronic literature searches were 
performed using Medline and Psychlit using broad search terms relating to TRD. Study 
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says that agents that potentiate both serotonin and noradrenaline may allow more 
patients to achieve full remission. Attention must be paid to dose titration and length of 
treatment courses in TRD. Augmentation with lithium and switching within 
antidepressant class or between classes can often improve symptoms but efficacy of 
other augmentation approaches remains uncertain .Antidepressant combinations and 
addition of atypical antipsychotics can be useful but combinations of predominantly 
serotonergic antidepressants should be avoided. Electroconvulsive therapy retains an 
important role in TRD but pharmacological treatments need to be continued 
concomitantly. They conclude that good improvement is seen in TRD after vigorous 
antidepressant treatment but most patients continue to have lower grade 
symptomatology. Most subjects with TRD continue to be symptomatic even after 
vigorous antidepressant treatment with good improvement in the majority but few 
reaching asymptomatic status. Subjects with chronic depression in the NIMH 
Collaborative Depression Study tended to continue at a lower level of severity over 
time, more like dysthymia than chronic depression though recovery was possible even 
after an episode lasting many years. They suggest that the best approach in treatment of 
resistant depression appears to be vigorous pharmacological treatment with high dose 
single of combination antidepressant therapy combined with later intensive 
psychological approaches and careful follow-up to avoid recurrence. 
 
 
3.13 Comparisons of the Efficacy and Tolerability of Extended-Release 
Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression A 
Double-Blind, Randomized Pilot Study in a Chinese Population 
 
Yiru Fang et al (2010) compared the efficacy and tolerability of antidepressants switch 
with extended-release venlafaxine (venlafaxine-XR), mirtazapine, and paroxetine in 
Chinese patients with major depressive disorder who had 2 consecutive unsuccessful 
antidepressant trials. In this one hundred fifty adult patients with treatment-resistant 
depression according to their medical records and/or response to current treatments 
were randomly assigned to receive fixed-dosage treatment of venlafaxine-XR 225 mg/d 
(n = 50), mirtazapine 45 mg/d (n = 55), or paroxetine 20 mg/d (n = 45) for 8 weeks. 
Here the primary outcome was the remission rates that were defined as a score 7 or 
lower on the 17-item Hamilton Rating Scale for Depression (HRSD-17). Secondary 
outcomes included the remission rate defined by the Self- 
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Rating Depression Scale of 50 or lower and the response rate defined by a 50% 
reduction or greater on the HRSD-17 total score, and the improvement of patients‟ 
general health functions. The completion rates were 82% for venlafaxine-XR, 81.8% 
for mirtazapine, and 82.2% for paroxetine. Only one patient in paroxetine arm 
discontinued the study owing to an adverse event. The remission rates based on the 
HRSD-17 were 42.0% for venlafaxine-XR, 36.4% for mirtazapine, and 46.7% for 
paroxetine. There were no statistical significances between treatment arms in remission 
rates. Similarly, there were also no significant differences between groups in secondary 
outcome measure. Venlafaxine-XR, mirtazapine, and paroxetine were equally effective 
in the treatment of Chinese patients with major depressive disorder who failed at least 
2 previous antidepressant treatments. The study concluded that selecting any of these 3 
antidepressants as a third-step antidepressant is a reasonable choice for this group of 
patients. 
 
 
3.14 Management of Clozapine-Resistant Schizophrenia 
 
Rob W. Kerwin & Anusha Bolonna (2005), suggested that the incidence of treatment 
resistance in schizophrenia (failure to respond to antipsychotic therapy) is about 20%. 
The National Institute for Clinical Excellence recommends that clozapine be used for 
schizophrenia resistant to another atypical antipsychotic. In this review, they focus on 
patients who are also resistant to clozapine given in adequate dosage for sufficient 
duration. They suggests that switching from clozapine to a previously untried atypical 
(e.g. olanzapine, risperidone, quetiapine) might be of benefit in partial treatment 
resistance. In more difficult cases, augmentation of clozapine with benzamides 
(sulpiride, amisulpride) and anti-epileptics (lamotrigine) shows some success. In 
extreme treatment resistance, a strategy is recommended that combines the proven best 
drug for the particular patient and psychosocial treatments. There is also reasonable 
evidence to suggest that augmentation strategies with sulpiride, amisulpride and 
lamotrigine are useful in treatment resistance, but no indication as to which patient will 
benefit from which strategy. 
 
 
3.15 Risperidone in Treatment-Refractory Schizophrenia 
 
Donna A. Wirshing et al (2000), conducted a four week, double blind, fixed dose 
comparison trial that was followed by a 4-week, flexible-dose phase. Sixty-seven 
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medication-unresponsive subjects were randomly assigned to treatment with 
risperidone (N=34) or haloperidol (N=33). Measures of clinical change were quantified 
by them using standard psychopathologic and neuromotor instruments. They suggested 
that risperidone demonstrated clinical efficacy superior to that of haloperidol on the 
total Brief Psychiatric Rating Scale (BPRS) after the first 4 weeks of treatment. 
Risperidone did not show any advantage over haloperidol after an additional 4 weeks. 
Overall improvement on the BPRS at 4 weeks was significantly better for the 
risperidone group (24%) than for the haloperidol group (11%). Risperidone-treated 
subjects were significantly less likely than haloperidol-treated subjects to require 
concomitant anticholinergic medication after 4 weeks (20% versus 63%); they also had 
significantly less observable akathisia (24% versus 53%) and significantly less severe 
tardive dyskinesia. Baseline characteristics that correlated significantly with 
risperidone response were positive symptoms, conceptual disorganization, akathisia, 
and tardive dyskinesia. They concluded that risperidone was better tolerated and more 
effective in a subset of patients with treatment-refractory schizophrenia. Positive 
psychotic symptoms and extrapyramidal side effects at baseline appear to be powerful 
predictors of subsequent response to risperidone. 
 
 
3.16 Randomized Controlled Trial of Effect of Prescription of Clozapine Versus 
Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia 
 
Shon W. Lewis et-al( 2006), conducted a double blind study on 136 people aged 18– 
65 with DSM-IV schizophrenia and related disorders whose medication was being 
changed because of poor clinical response to 2 or more previous antipsychotic drugs. 
Participants were randomly allocated to clozapine or to one of the class of other SGA 
drugs (risperidone, olanzapine, quetiapine, amisulpride) as selected by the managing 
clinician. Outcomes were assessed blind to treatment allocation. One-year assessment 
were carried out in 87% of the sample. They assessed that treatment comparison 
showed no statistically significant advantage for commencing clozapine in Quality of 
Life score (3.63points; CI: 0.46–7.71; p = .08) but did show an advantage in Positive 
and Negative Syndrome Scale (PANSS) total score that was statistically significant (– 
4.93 points; CI:8.82 to 1.05; p = .013) during follow-up. They suggested that clozapine 
showed a trend toward having fewer total extrapyramidal side effects and at 12 weeks 
participants who were receiving clozapine reported that their mental health was 
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significantly better compared with those receiving other SGA drugs. In conclusion, in 
people with schizophrenia with poor treatment response to 2 or more antipsychotic 
drugs, there is an advantage to commencing clozapine rather than other SGA drugs in 
terms of symptom improvement over 1 year. 
 
 
3.17 Pharmacotherapy for Treatment Resistant Schizophrenia 
 
Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler, Bruce R Russell (2011), 
conducted a study that suggests that Clozapine has been shown to be more effective 
than other antipsychotics in treatment-resistant populations in however, the occurrence 
of adverse effects, some of which are potentially life-threatening, are important 
limitations. In addition to those who are intolerant to clozapine, only 30% to 50% 
experience clinically significant symptom improvement. This review describes the 
recent evidence for treatment strategies for people not responding to non-clozapine 
antipsychotic agents and people not responding or only partially responding to 
clozapine. In addition to people with treatment-resistant schizophrenia, studies suggest 
that clozapine may be useful for those at high risk of suicide or aggression. The adverse 
effects of clozapine are significant, ranging from acute events such as agranulocytosis 
to insidious weight gain and the onset of the metabolic syndrome. Many studies 
reported that clozapine treatment produced the greatest increase in BMI and/or body 
weight, closely followed by olanzapine. 
 
 
3.18 Effectiveness of Second-Generation Antipsychotics in Patients with 
Treatment- Resistant Schizophrenia: A Review and Meta-Analysis of Randomized 
Trials 
 
Miranda Chakos, M.D. et al (2001), conducted a review and meta-analysis of studies 
that compared the efficacy and tolerability of typical and second-generation 
antipsychotics for patients with treatment-resistant schizophrenia. A systematic search 
revealed 12 controlled studies (involving 1,916 independent patients), which were 
included in the review. The meta-analysis confirmed that treatment-resistant 
schizophrenic patients have more favourable outcomes when treated with clozapine 
rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total 
score. The results of a meta-analysis indicated that clozapine exhibits superiority over 
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typical antipsychotics in terms of both efficacy (as measured by improvement in 
overall psychopathology) and safety (in terms of reduced extrapyramidal side effects). 
Of the 10 comparisons of second-generation versus typical antipsychotics, six found a 
significant difference that favoured the second-generation antipsychotic on measures of 
treatment efficacy; four found no significant difference between treatments. Five of the 
seven studies that compared clozapine to a typical antipsychotic medication in 
treatment-resistant patients found a significant difference favouring clozapine. 
 
 
3.19 Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of 
Patients with Chronic Schizophrenia and Schizoaffective Disorder 
 
Jan Volavka, et al (2002), conducted a double-blind trial, in 157 in patients with a 
history of suboptimal treatment response were randomly assigned to treatment with 
clozapine, olanzapine, risperidone, or haloperidol for 14 weeks (an 8-week escalation 
and fixed dose period followed by a 6-week variable- dose period). They suggests that 
Clozapine, risperidone, and olanzapine (but not haloperidol) resulted in statistically 
significant improvements in total score on the Positive and Negative Syndrome Scale. 
Improvements seen in total and negative symptom scores with clozapine and 
olanzapine were superior to haloperidol. The study reveals that atypical drugs, 
particularly olanzapine and clozapine, were associated with weight gain. They conclude 
that the effects of atypical antipsychotics in this population were statistically significant 
but clinically modest. The overall pattern of results suggests that clozapine and 
olanzapine have similar general antipsychotic efficacy and that risperidone may be 
somewhat less effective. Clozapine was the most effective treatment for negative 
symptoms. 
 
 
3.20 The practical management of refractory schizophrenia – the Maudsley 
Treatment review and Assessment Team service approach 
 
K. Beck et al (2014), conducted a study to describe the practical approach to the 
community management of treatment-resistant schizophrenia (TRS). They did a 
descriptive review of an approach to the assessment and management of patients with 
TRS, including the community titration of clozapine treatment, and a report of the 
management recommendations for the first one hundred patients assessed by the 
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Treatment Review and Assessment Team (TREAT). They suggested a standardized 
model for the community assessment, management and titration of clozapine. 137 
patients have been referred to this service and 100 patients (72%) attended for 
assessment. Of these, 33 have been initiated on clozapine while fifteen have had 
clozapine recommended but have not wished to undertake clozapine treatment. Other 
management options recommended have included augmentation strategies and long-
acting injectable antipsychotics. They concluded their study that the service had 
increased the number of patients receiving community assessment and initiation of 
clozapine by five-fold relative to the rate prior to the establishment of the service. The 
large number of referrals and high attendance rate indicates that there is clinical 
demand for the model. Systematic evaluation is required to determine the clinical and 
cost-eﬀ ectiveness of this model and its potential application to other clinical settings. 
 
 
3.21 Role of Aripiprazole in Treatment Resistant Schizophrenia 
 
 
Nilfar Mossaheb, Rainer M Kaufmann (2012), conducted this study to evaluate the 
evidence for aripiprazole as a potential strategy in monotherapy or combination therapy 
for patients with treatment-resistant schizophrenia. Since no recommendation can be 
made on the basis of the currently available data as evidence for aripiprazole 
monotherapy and for the combination of aripiprazole with psychotropics other than 
clozapine is scant. The findings of four randomized controlled trials with respect to 
changes in psychopathology seem less conclusive. The most commonly found 
beneficial effects of this study are better metabolic outcomes and indicators of the 
possibility of reducing the clozapine dose. However, other side effects, such as 
akathisia, were repeatedly reported. This study suggests that combining aripiprazole 
with clozapine in clozapine-resistant or clozapine-intolerant patients seems to be 
worthy of further investigation from the pharmacological and clinical points of view. 
 
 
3.22 Risperidone versus Clozapine in Treatment-Resistant Chronic 
Schizophrenia: A Randomized Double-Blind Study 
 
G. Bondolfi et-al (2000), conducted this study to compare the short-term efficacy and 
safety of risperidone and clozapine in treatment-resistant chronic schizophrenic 
patients. In this controlled double-blind, multicenter study, 86 in patients with chronic 
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schizophrenia (DSM- III-R), who were resistant to or intolerant of conventional 
neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks 
after a 7-day washout period. After a 1-week dose-titration phase, doses were fixed at 6 
mg/day of risperidone and 300 mg/day of clozapine for 1 week and then adjusted 
according to each patient‟s response. The final mean doses were 6.4 mg/day of 
risperidone and 291.2 mg/day of clozapine. Treatment efficacy and safety were 
evaluated with several well-known rating scales. Based on their study they noted that 
both risperidone and clozapine significantly reduced the severity of psychotic 
symptoms (scores on the Positive and Negative Syndrome Scale and the Clinical 
Global Impression scale) from baseline, with no significant between-group differences. 
At endpoint, 67% of the risperidone group and 65% of the clozapine group were 
clinically improved (reduction of 20% or more in total Positive and Negative Syndrome 
Scale score). Risperidone appeared to have a faster onset of action. In both groups extra 
pyramidal symptoms and other adverse events were few, and their severity was 
generally mild. Neither group showed evidence of a relation between drug plasma 
concentrations and clinical effectiveness and they concluded their study as Risperidone 
was well tolerated and as effective as medium doses of clozapine in patients with 
chronic schizophrenia who had been resistant to or intolerant of conventional 
neuroleptics. 
 
 
3.23 Randomized controlled trial of occupational therapy in patients with 
treatment-resistant schizophrenia 
 
Patrícia Cardoso Buchain et-al (2003), compared two groups of patients with TRS. 
The experimental group (EG) received psychopharmacological treatment with 
clozapine plus sessions of occupational therapy (OT) and the control group (CG) 
received only clozapine. To evaluate the outcome of the study, The Scale for 
Interactive Observation in Occupational Therapy (EOITO) was employed. The duration 
of the study was 6 months and patients were rated at baseline and monthly totaling 7 
assessments. EOITO was independently applied by two occupational therapists with 
high reliability rates (Kappa=0.90, p=0.001). Repeated measures of analyses of 
variance and the evaluation of the standardized effect sizes were used for statistical 
analyses. The study showed that the EG showed that the OT intervention was effective 
along the whole period of observation, mainly from the 4th month to the end 
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of the study. This study concluded that in patients with TRS, the combination of OT 
and clozapine showed to be more effective than the use of clozapine alone. OT may 
represent an additional therapeutic option for patients with TRS. 
 
 
3.24 Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone 
in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical 
Antipsychotic Treatment 
 
Joseph P. McEvoy et al (2006), conducted a study that compares switching to 
clozapine with switching to another atypical antipsychotic in patients who had 
discontinued treatment with a newer atypical antipsychotic in the context of the 
Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. 
Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, 
risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of 
inadequate efficacy, were randomly assigned to open-label treatment with clozapine 
(N=49) or blinded treatment with another newer atypical anti- psychotic not previously 
received in the trial (olanzapine [N=19], quetiapine [N= 15], or risperidone 
[N=16]).The study suggests that time until treatment discontinuation for any reason 
was significantly longer for clozapine (median=10.5 months) than for quetiapine 
(median= 3.3), or risperidone (median=2.8), but not for olanzapine (median=2.7). Time 
to discontinuation because of inadequate therapeutic effect was significantly longer for 
clozapine than for olanzapine, quetiapine, or risperidone. The study reveals that at 3-
month assessments, Positive and Negative Syndrome Scale total scores had decreased 
more in patients treated with clozapine than in patients treated with quetiapine or 
risperidone but not olanzapine. The study concludes that for these patients with 
schizophrenia who prospectively failed to improve with an atypical antipsychotic, 
clozapine was more effective than switching to another newer atypical antipsychotic. 
 
 
3.25 Current Perspectives In The Treatment Of Resistant Schizophrenia 
 
 
R.K.Solanki et al (2009), this study summarizes the current knowledge based on the 
diagnosis and management of treatment resistant schizophrenia. While the prevalence 
of treatment resistant schizophrenia is definition dependent, estimates have ranged 
from 30% to up to 60%. This study first looks into the various diagnostic criteria of 
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treatment resistant schizophrenia. Then the study reviewed about the 
pharmacotherapeutics of its management and they suggest that clozapine emerges to be 
the gold standard. In addition risperidone and high dose Olanzapine also emerge as 
clinically useful options. Other emerging adjunctive treatment options are equally 
addressed in this study. Though clozapine appears to emerge as the gold standard for 
treatment resistant schizophrenia, however it still lacks effect in some of the subjects. 
Nevertheless augmentation studies have shown promising results. Other atypical 
antipsychotics esp. Risperidone and high dose Olanzapine also show response in some 
resistant cases. Studies till date indicate that psychosocial interventions have important 
role in the management of the patients of treatment resistant schizophrenia and this 
field needs more exploration. The reason for this treatment resistance is not clearly 
addressed in this study, but the role of rapid metabolizers, pharmacogenetics and single 
nucleotide polymorphisms may explain the same in the time to come. 
 
 
3.26 Clozapine v/s Conventional Antipsychotic Drugs For Treatment Resistant 
Schizophrenia: A Re-examination 
 
Joanna Moncrieff (2003), conducted this study to re-evaluate the results of relevant 
trials by comparing clozapine with other conventional antipsychotics and thus 
investigating the sources of heterogenicity, since there exist a consensus that clozapine 
is more effective than conventional antipsychotic drugs for treatment resistant 
schizophrenia. She inspected individual studies with assessment of clinical relevance of 
results. Meta-regression analysis was performed to investigate sources of 
heterogeneity. Based on the examination of ten trials, recent large scale studies have 
not found a substantial advantage for clozapine, especially in terms of clinically 
relevant effect. Meta regressions showed that shorter study duration, financial support 
from a drug company and higher baseline symptoms score consistently predicted 
greater advantage of clozapine. And she concluded the study it may be inappropriate to 
combine studies in meta-analysis, given the degree of heterogeneity between their 
findings. The benefits of clozapine compared with conventional treatment may not be 
substantial. 
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3.27 Augmentation of Olanzapine in Treatment Resistant Schizophrenia 
 
 
Mathias Zink (2005), claims up to 40% of patients with schizophrenic psychoses have 
symptoms that are resistant to monotherapy with antipsychotic drugs. In consequence, 
combinations of drugs are often used, especially based on the antipsychotic agents 
clozapine and Olanzapine because of their broad receptor-interaction profile. Thus with 
an aim of providing a critical overview of the published results of Olanzapine 
augmentation, he conducted this systemic review. He performed a systematic database 
search on MEDLINE and BIOSIS (Ovid), looking for publications on augmented 
therapeutic approaches involving Olanzapine, by using the search terms like 
“augmentation,” “combination,” “schizophrenia,” ”Olanzapine,” and the names of 
other antipsychotic drugs and non-antipsychotic agents, including brand names, 
spanning publications from 1966 until the end of December 2004. Based on critical 
evaluation of data obtained he reach on an assumption, of 14 reports dealing with 8 
different antipsychotic augmentation strategies (83 patients), only 1 trial, of sulpiride 
Olanzapine therapy, was performed in a randomized manner. Based on clinical 
observation, a significant number of the treatments led to favorable results. In contrast 
to adjuvant therapy with antipsychotic drugs, augmentation of Olanzapine with glycine, 
antidepressants or mood stabilizers was evaluated in well-designed clinical trials (8 
publications, 989 patients), with distinct improvements of positive and/or negative 
symptoms reported. And then he concluded the review as the combination of 
Olanzapine with antidopaminergic atypical antipsychotic agents seems to follow a 
neurobiological rationale. The augmentation trials with nonantipsychotic agents, for 
example, mood stabilizers, were successful and showed that randomized and placebo-
controlled trials are feasible. Therefore, systematic evaluations of antipsychotic agents 
as adjuvant therapy are possible as well as necessary to determine the benefits and risks 
of any new treatment strategy. 
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 4. METHODOLGY 
 
 
4.1 Study Setting: 
 
The study was carried out in KIMS Al Shifa Hospital located in Perinthalmanna at 
Malappuram district. It is a 750 bedded multispecialty tertiary level referral hospital. 
The hospital is unique and people from all over the country come and avail its 
facilities. The various specialties include general medicine, obstetrics and gynecology, 
pediatrics and neonatal, neurosciences, anesthesiology, orthopedics, radiology, 
nephrology, pulmonology and critical care, cardiology and cardiothoracic surgery, 
microbiology, pathology and hematology, laparoscopic surgery, ENT, dental and 
maxillofacial surgery, neurology, ophthalmology, physical medicine and rehabilitation, 
dialectology, surgical gastroenterology, oncology, psychiatry. The hospital is also 
equipped with modern diagnostic facilities like CT scan, MRI scan, ultra Sound 
sonography, digital subtraction angiography, treadmill, color doppler etc. The hospital 
also has twelve hi-tech operation theatres, Intensive Care Unit, intensive cardiac care 
unit, catheterization balloon valvuloplasty, coronary stenting, kidney transplantation 
unit with haemodialysis machines and an assisted reproductive technology center. 
 
 
4.2 Study Design: 
 
It is an observational descriptive study to determine the demographic profile and 
management strategies of treatment resistant schizophrenia and treatment resistant 
depression. 
 
 
4.3 Study Period: 
 
The study spanned over duration of 6 months, commencing from November 2016 to 
April 2017. 
 
 
4.4 Ethics Clearance: 
 
The study was approved by the ethics committee of Kims AlShifa hospital Pvt. Ltd and 
an official consent was provided by the concerned authority for the purpose of 
conducting the study. It was certified by the Institutional Ethical Committee met on 
20th December 2017 and approved the proposal of the dissertation as per letter no 
KAS/ADMN/AC/EC/154/2017. 
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4.5 Study Criteria: 
 
The patients for the study were selected on the basis of the following inclusion and 
exclusion criteria during the study period of 6 months. 
 
 
4.5.1 Inclusion Criteria: 
 
 Age between 18 – 65 years.

 Patients who can give informed consent.

 Patients satisfying the diagnostic criteria for treatment resistant schizophrenia.

 Patients satisfying the diagnostic criteria for treatment resistant depression.
 
 
4.5.2 Exclusion Criteria: 
 
 Age below 18 years and above 65 years.

 Patients with epilepsy, other substantial organic or neurologic disease, or 
clinically relevant abnormal ECGs or laboratory tests.

 Patients with a history of alcohol or drug abuse within the previous 12 months.

 Patients with another psychiatric disorder as comorbid illness.
 
 
4.6 Study Tools 
 
 
4.6.1 Data Collection Form: 
 
A data collection form (Annexure III) was designed to collect information necessary 
for the study. The form consists of the following details: 
 
1. Patient demographics. 
 
2. Presenting symptoms 
 
3. Physical examination. 
 
4. Final diagnosis. 
 
5. Past medical history. 
 
6. Past medication history. 
 
7. Family history. 
 
8. Social history. 
 
9. Symptom assessment. 
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10. Medication chart containing name of the drug, dose, route of administration and 
frequency, date started and date stopped. 
 
11. Electroconvulsive therapy. 
 
12. Laboratory reports. 
 
13. Adverse drug reactions. 
 
 
4.6.2. Informed Consent 
 
The nature, type or intention of the study was explained to the patients by direct patient 
interaction. Participants were then given time to decide whether or not to participate. If 
they decided to participate, written consent was obtained. Patient consent form is 
included in Annexure  
 
 
4.7. Sources of Data 
 
• Patients case record. 
 
• Patient‟s prescription. 
 
• Direct interactions with physician. 
 
• Montgomery Asberg Depression Rating Scale. 
 
• Positive and Negative Syndrome Scale. 
 
 
4.7.1. Data Collection 
 
Demographic data, details of co morbid conditions etc were collected from patient‟s 
case records. Patient case records were reviewed to collect the details of disease, 
medications, social and family histories etc. Data relevant to the study were obtained 
and recorded using Hamilton depression rating scale and positive and negative 
syndrome scale. 
 
The baseline characteristics were collected at the time of recruitment of patients in the 
study. 
 
 
Scales used in data collection 
 
• Montgomery Asberg Depression Rating Scale. 
 
• Positive And Negative Syndrome Scale. 
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4.7.1.1 Patient case record 
 
Patient demographics, co morbidities, social and family history were obtained from 
patient case record available in both electronic and written format maintained in the 
hospital. 
 
 
4.7.1.2 Patients prescription 
 
Electronic prescription were checked and data regarding current therapy and past 
medication were collected. Written prescriptions are obtained from patients during 
each hospital visit for cross verification. 
 
 
4.7.1.3 Direct interaction with physician 
 
Discussing the appropriateness of the therapy and the rationality of each drug based on 
evidence based literature review. 
 
 
4.7.1.4. Montgomery Asberg Depression Rating Scale 
 
Rating Clinician-rated 
 
Administration time 10–15 minutes 
 
Main purpose: To assess the severity of symptoms of depression 
 
Population: Adults, adolescents and children 
 
The MADRS was one of the rating scales developed to measure the severity of 
depressive symptoms, and is widely used today in both clinical and research settings. 
The scale consists of 10 items, each defined by a series of symptoms, and measures 
severity of depressive episodes. This scale would be more sensitive to the changes 
brought on by antidepressants and other form of treatment than the Hamilton 
Depression Rating Scale was. 
 
 
Scoring 
 
Each item is scored on a scale of 0 (not present) to 6 (severe), with a total score range 
of 0–60, where <19 indicates mild depression, 20–34 moderate depression and >34 
severe depression. 
 
 
4.7.1.5. Positive And Negative Syndrome Scale (PANSS) 
Rating: Self or family report or clinician rated 
Administration time 45 minutes 
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Main purpose: To assess severity of symptoms of schizophrenia. 
 
Population: Adults and adolescents aged 15 and older. 
 
PANSS is a medical scale used for measuring symptom severity of patients with 
schizophrenia. It is widely used in the study of antipsychotic therapy. The name refers 
to the two types of symptoms in schizophrenia, as defined by the American Psychiatric 
Association; positive symptoms, which refer to an excess or distortion of normal 
functions and negative symptoms, which represents a diminution or loss of normal 
functions. To assess a patient using PANSS, an approximately 45 minute clinical 
interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based 
on the interview as well as reports of family members or primary care hospital workers. 
 
 
Scoring 
 
The scale consist of a positive scale which contains 7 items (minimum score = 7, 
maximum score = 49), a negative scale with 7 items (minimum score = 7, maximum 
score = 49), and a general psychopathology scale which contains 16 items (minimum 
score = 16, maximum score = 112). Being considered “mildly ill” according to the 
Clinical Global Impressions approximately corresponded to a PANSS total score of 58, 
“moderately ill” to a PANSS of 75, “markedly ill” to a PANSS of 95 and “severely ill” 
to a PANSS of 116. 
 
 
4.8. Study Procedure 
 
The patients in Psychiatry department diagnosed with treatment resistant schizophrenia 
and treatment resistant depression were selected based on inclusion and exclusion 
criteria. Demographic profile of the patients were collected from their case files. The 
severity of symptoms of TRS patients were assessed using PANSS. The severity of 
symptoms of TRD patients were assessed using MADRS. Treatments were given to the 
patients according to their symptoms severity. Dose adjustments were done based on 
individual patient aspects. Effectiveness of the therapy were measured using PANSS 
and MADRS scale scorings. The collected data were analyzed, categorized and entered 
into Ms. Excel format. Statistical analysis of the collected details was done at the last 
stage of study. 
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4.9. Statistical Analysis 
 
 
Type of sample test proposed to be used for determining conclusion 
 
The collected data for the study were compiled and analyzed for drawing inferences 
employing statistical techniques. The test used was “Wilcoxon signed rank test”. It is a 
non-parametric statistical hypothesis test used when comparing two related samples, 
matched samples or repeated measurements on a single sample to assess whether their 
population mean ranks differ. 
 
The steps for calculation of Wilcoxon signed rank test is: 
 
1. State the null hypothesis. 
 
2. Calculate  each  paired  difference,  di  =  xi  −  yi,  where  xi,  yi  are  the  pairs  of 
 
observations. 
 
3. Rank the dis, ignoring the signs (i.e. assign rank 1 to the smallest |di|, rank 2 to the 
next etc.) 
 
4. Label each rank with its sign, according to the sign of di. 
 
5. Calculate W
+
, the sum of the ranks of the positive dis, and W
−
, the sum of the ranks 
of the negative dis. (As a check the total, W
+
 + W
−
, should be equal to n(n+1) /2 , 
where n is the number of pairs of observations in the sample). 
 
Z = W - mw ± 0.5 
 
σ w  
 
 
Where, σ w = n (n + 1) (2n + 1) 
   
 6  
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5. RESULTS 
 
 
 
 
As per the inclusion and exclusion criteria, a total of 25 patients were enrolled in the 
study for treatment resistant schizophrenia and 27 patients were enrolled in the study 
for treatment resistant depression. 
 
 
 
 
5.1 CLINICAL DEMOGRAPHICS 
 
 
 
 
5.1.1 THE GENDER WISE DISTRIBUTION OF PATIENTS WITH 
TREATMENT RESISTANT SCHIZOPHRENIA: 
 
Out of the data collected from 25 patients who visited at the Psychiatry department, 13 
patients (52%) were males and 12 patients (48%) were females. 
 
 
 
 
 
FIG. 1.GENDER WISE DISTRIBUTION OF TRS 
PATIENTS  
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5.1.2 THE GENDER WISE DISTRIBUTION OF PATIENTS WITH 
TREATMENT RESISTANT DEPRESSION: 
 
Out of the data collected from 27 patients who visited the Psychiatry department, 12 
patients (44.4%) were males and 15 (55.6%) females. 
 
 
FIG. 2. GENDER WISE DISTRIBUTION OF TRD 
PATIENTS 
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5.1.3 AGEWISE DISTRIBUTION OF THE PATIENTS WITH TREATMENT 
RESISTANT SCHIZOPHRENIA: 
 
The mean age = 37.12 ± 7.79 years (Range- 26 to 57 years). 
 
Age category: Below 25=0%, 26 to 30=24% (n=6), 31 to 35=20% (n=5), 36 to 
40=28% (n=7), 41 – 45 =16% (n=4).and above 45 =12% (n=3). 
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FIG. 3. AGEWISE DISTRIBUTION IN TRS PATIENTS 
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5.1.4 AGEWISE DISTRIBUTION OF THE PATIENTS IN PATIENTS WITH 
TREATMENT RESISTANT DEPRESSION: 
 
 
 
The mean age =49 ± 10.7 years (Range- 31 to 65 years). 
 
 
Age category: Below 30=0%, 31 to 35=7.4% (n=2), 36 to 40=18.5% (n=5), 41 to 
45=14.8% (n=4) and above 45=59.3% (n=16). 
 
 
 
 
 
 
FIG. 4. AGEWISE DISTRIBUTION IN TRD PATIENTS 
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5.1.5 MARITAL STATUS IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
In this study, out of the 25 patients 15 patients (60%) were married, 5 patients (20%) 
were single and 5 patients (20%) were divorcee. 
 
FIG. 5. MARITAL STATUS IN TRS PATIENTS  
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5.1.6 MARITAL STATUS IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
In this study, out of 27 patients, 25 patients (92.6%) were married and 2 patients 
(7.4%) were single. 
 
FIG. 6. MARITAL STATUS IN TRD PATIENTS 
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5.1.7 EDUCATIONAL QUALIFICATION IN PATIENTS WITH TREATMENT 
RESISTANT SCHIZOPHRENIA: 
 
In this study, out of the 25 patients about 52.0% (n=13) had an education ≤SSLC, 
about 36% (n=9) had an education of plus two and about 12% (n= 3) had an education 
of degree or above. 
 
FIG. 7. EDUCATIONAL QUALIFICATION IN TRS PATIENTS  
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5.1.8 EDUCATIONAL QUALIFICATION IN PATIENTS WITH TREATMENT 
RESISTANT DEPRESSION: 
 
In this study, about 66.7% (n=18) had an education ≤SSLC, about 18.5% (n=5) had an 
education of plus two and about 14.8% (n=4) had an education of degree or above. 
 
FIG. 8. EDUCATIONAL QUALIFICATION IN TRD PATIENTS  
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5.1.9 FAMILY HISTORY OF ANY PSYCHIATRIC CONDITIONS IN 
PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA: 
 
Of the total 25 patients, about 72% (n=18) had a family history of any psychiatric 
conditions and 28% (n=7) had no family history. 
 
FIG. 9. FAMILY HISTORY OF ANY PSYCHIATRIC 
CONDITIONS IN TRS PATIENTS  
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5.1.10 FAMILY HISTORY OF ANY PSYCHIATRIC CONDITIONS IN 
PATIENTS WITH TREATMENT RESISTANT DEPRESSION: 
 
 
Of the total 27 patients, about 74.1% (n=20) had a family history of any psychiatric 
conditions and 25.9% (n=7) had no family history. 
 
FIG. 10. FAMILY HISTORY OF ANY PSYCHIATRIC 
CONDITIONS IN TRD PATIENTS  
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5.2 MANAGEMENT STRATEGIES 
 
 
 
 
5.2.1 CHOICE OF THERAPY IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
 
Clozapine + Amisulpride combination (20%, n=5) was majorly used. Least 
consumption was Clozapine + Olanzapine + Amisulpride + Risperidone + Iloperidone 
combination and Clozapine + Haloperidol + Olanzapine + Risperidone combination 
(4%, n=1). Clozapine was given alone in one patient (4%). 
 
 
 
 
TABLE NO. 1 CHOICE OF THERAPY IN TRS PATIENTS 
S. No. DRUGS Frequency Percent 
    
1. Clozapine + Amisulpride 5 20.0% 
2. Clozapine + Aripiprazole 4 16.0% 
3. Clozapine + Olanzapine + Amisulpride 3 12.0% 
4. Clozapine + Risperidone 3 12.0% 
5. Clozapine + Haloperidol  + Olanzapine + ECT 3 12.0% 
6. Clozapine + Olanzapine + Risperidone 2 8.0% 
7. 
Clozapine + Olanzapine + Amisulpride + ECT +  
8.0% Risperidone 2 
    
8. Clozapine + Olanzapine + Amisulpride +   
Risperidone + Iloperidone 1 
 
 4.0% 
   
9. Clozapine 1 4.0% 
 Clozapine + Haloperidol + Olanzapine +   
10. Risperidone 1 4.0% 
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5.2.2 CHOICE OF THERAPY IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
 
Sertraline + Venlafaxine + Sodium valproate (22.2%, n=6) was majorly used. Least 
consumption was Sertraline + Amitryptiline + Venlafaxine + Lithium + Sodium 
valproate combination and Sertraline + Venlafaxine + Bupropion + Lithium + Sodium 
valproate + ECT combination (3.7%, n=1). 
 
 
 
 
TABLE NO. 2 CHOICE OF THERAPY IN TRD PATIENTS 
S. No. DRUGS Frequency Percent 
    
1 Sertraline + Venlafaxine + Sodium valproate 6 22.2% 
2 Sertraline + Venlafaxine + Escitalopram 4 14.8% 
3 Venlafaxine + Sodium valproate + Escitalopram 3 11.1% 
4 Venlafaxine + Lithium + Escitalopram 3 11.1% 
5 Sertraline + Amitryptiline + Venlafaxine 3 11.1% 
6 Venlafaxine + Lithium + Escitalopram + ECT 2 7.4% 
7 Mirtazapine + Lithium + Sodium valproate 2 7.4% 
8 Bupropion + Lithium + Sodium valproate +   
 Escitalopram 2 7.4% 
9 Sertraline + Amitryptiline + Venlafaxine +   
 Lithium + Sodium valproate 1 3.7% 
10 Sertraline + Venlafaxine + Bupropion + Lithium +   
 Sodium valproate + ECT 1 3.7% 
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5.2.3 DOSE ANALYSIS IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
Clozapine 100 mg was the mostly used (n=13) dose in this study. Clozapine 50 mg 
dose was also used widely (n=9). Olanzapine 20 mg was also used in many patients 
(n=6). Haloperidol 5mg, 20 mg, Olanzapine 210 mg, Aripiprazole 10mg, 30mg and 
Iloperidone 12mg were used rarely. 
 
TABLE NO. 3 DOSE ANALYSIS IN TRS PATIENTS  
  NUMBER OF 
DRUG DOSES GIVEN PER PATIENTS TREATED 
 DAY  
 25 mg 3 
   
CLOZAPINE 50 mg 9   
   
 100 mg 13 
   
 5 mg 1 
   
HALOPERIDOL 
10 mg 2 
  
   
 20 mg 1 
   
 10 mg 4 
   
AMISULPRIDE 
20 mg 5 
  
 50 mg 2 
   
 7. 5 mg 3 
   
 20 mg 6 
OLANZAPINE 
  
30 mg 2 
   
 210 mg 1 
   
 1 mg 3 
RISPERIDONE   
2 mg 3  
   
 3 mg 3 
   
 10 mg 1 
ARIPIPRAZOLE 
  
15 mg 2  
   
 30 mg 1 
   
ILOPERIDONE 12 mg 1 
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5.2.4 DOSE ANALYSIS IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
 
Lithium 300 mg was widely used dose (n=11). Venlafaxine 150 mg was given in most 
of the TRD patients (n=8). Apart from 150 mg dose, venlafaxine was also given in 50 
mg (n=6), 75 mg (n=4) and 225 mg doses (n=2). Amitriptyline 100 mg, 150 mg and 
Bupropion 150 mg were the least used doses. 
 
 
 
TABLE NO. 4 DOSE ANALYSIS IN TRD PATIENTS 
DRUGS DOSE GIVEN PER DAY NO.OF PATIENTS 
  TREATED 
 25 mg 3 
SERTRALINE 
  
50 mg 5 
   
 100 mg 7 
   
 50 mg 6 
   
VENLAFAXINE 75 mg 5 
  
   
 150 mg 10 
   
 225 mg 2 
   
 100 mg 2 
BUPROPION   
150 mg 1  
   
LITHIUM 300 mg 11 
   
 125 mg 5 
SODIUM VALPROATE 
  
250 mg 6 
   
 500 mg 4 
   
MIRTAZAPINE 15 mg 2 
   
 10 mg 6 
ESCITALOPRAM 
  
20 mg 5 
   
 40 mg 3 
   
 100 mg 2 
   
AMITRIPTYLINE 150 mg 1 
  
   
 200 mg 1 
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5.2.5 DRUG USE PATTERN IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
Clozapine was given to all the patients treated (100%, n=25). Amisulpride was given in 
44% (n=11) of patients. Olanzapine was used in 48% (n=12) and risperidone was used 
in 36% (n= 9) of patients. ECT was given for 50% (n=5) of the total patients. 
Aripiprazole was used in 16% (n=4) of patients. Iloperidone was given only to one 
patient (4%). 
 
 
 
 
FIG. 11 DRUG USE PATTERN IN TRS PATIENTS  
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5.2.6 DRUG USE PATTERN IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
 
Venlafaxine was given to 85.19% (n=23) of the patients. Sertraline was given in 55.6% 
(n=15) of patients and escitalopram was given in 51.85% (n=14) of patients. Sodium 
valproate was used in 44.4% (n=12) and lithium was used in 40.74% (n=11) of 
patients. Amitriptyline was used in 14.8% (n=4) of patients. ECT was given for 11.1% 
(n=3) and bupropion and mirtazapine was used in 7.4% (n=2) of patients. 
 
 
 
 
FIG. 12 DRUG USE PATTERN IN TRD PATIENTS  
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5.3 SCORING OF SYMPTOMS 
 
 
 
5.3.1 PANSS SCORING FOR PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
Initial PANSS score represents the severity of symptoms in treatment resistant 
schizophrenia before the treatment and final PANSS score represents the symptoms 
severity after treatment. Here initial PANSS score had a mean of 107.64 ± 30.89 and 
final PANSS score had a mean of 83.96 ± 25.33. The mean difference was 23.68. 
Wilcoxon Signed Ranks Test was used to test the significance and the study was 
significant with Z=4.378 and p=0.001 at 1% level of significance. 
 
 
 
 
 
TABLE NO. 5 PANSS SCORE IN TRS PATIENTS 
 
    Wilcoxon Signed Ranks 
   
Mean 
 Test 
PANSS Mean SD 
   
difference 
   
   
      
    Z  P value 
       
INITIAL 107.64 30.89     
   
23.68 4.378  0.001* 
FINAL 83.96 25.33     
       
 
 
* Significant at 1% level of significance 
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 5.3.2 MADRS SCORING FOR PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
 
Initial MADRS score represents the severity of symptoms in treatment resistant 
depression before the treatment and final MADRS score represents the symptoms 
severity after treatment. Here initial MADRS score had a mean of 40.11 ± 6.16 and 
final MADRS score had a mean of 24.85 ± 3.32. The mean difference was 15.26. 
Wilcoxon Signed Ranks Test was used to test the significance and the study was 
significant with Z=4.557 and p=0.001 at 1% level of significance. 
 
 
 
 
 
TABLE NO.6 MADRSS SCORE IN TRD PATIENTS 
 
    Wilcoxon Signed Ranks 
MADRS Mean SD 
Mean  Test 
difference       
Z 
 
P value      
       
INITIAL 40.11 6.16     
   
15.26 4.557  0.001* 
FINAL 24.85 3.32     
       
 
* Significant at 1% level of significance 
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5.4. ADR REPORTING 
 
 
 
 
 
5.4.1 ADRs OBSERVED IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
Weight gain (n=10), constipation (n=4), EPS (n=3), DM (n=3), sexual dysfunction 
(n=2) and tachycardia (n=1) were the observed ADRs in the 25 patients during the 
study period. 
 
 
 
 
 
FIG. 11. ADRs OBSERVED IN TRS PATIENTS  
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5.4.2 ADRs OBSERVED IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
 
Weight changes (n=8), sexual dysfunction (n=5) and GI problems (n=6) were 
the observed ADRs in the 27 patients during the study period. 
 
 
 
FIG. 12. ADRs OBSERVED IN TRD PATIENTS  
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5.4.3 CAUSALITY OF ADR IN PATIENTS WITH TREATMENT RESISTANT 
SCHIZOPHRENIA: 
 
 
When analysed on Naranjo ADR probability scale, majority of ADRs were rated as 
possible [n = 15 (65.22%)], followed by probable [n =8 (34.78%)]. 
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FIG. 13 CAUSALITY OF ADR IN TRS PATIENTS  
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5.4.4 CAUSALITY OF ADR IN PATIENTS WITH TREATMENT RESISTANT 
DEPRESSION: 
 
When analysed on Naranjo ADR probability scale, majority of ADRs were rated as 
possible [n = 14 (73.68%)], followed by probable [n = 5 (26. 32%)]. 
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FIG. 14 CAUSALITY OF ADR IN TRD PATIENTS  
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6. DISCUSSION 
 
 
 
 
Management of treatment resistant conditions of schizophrenia and depression were 
analyzed in the study. Evaluation and updating of the knowledge on these conditions 
and the therapies help clinicians in their effective patient care. The result of this study 
may be helpful for clinicians to provide an insight to treatment modalities given in our 
hospital setting and thereby improve their clinical perspective in this area. It is also 
very helpful for health system decision makers to reduce the incidence of adverse drug 
reactions and thereby the patient sufferings and cost of therapy. Understanding the 
demographic profile of the TRS and TRD patients will help healthcare practitioners 
better prepare for the problems caused by the world‟s rapidly expanding population. 
The importance of demography lies in its contribution to helping government and 
society better prepare to deal for the issues and demands of population growth, aging 
etc. Treatment resistant schizophrenia and treatment resistant depression are two major 
clinical challenges faced globally. Our study investigated the demographic profile and 
management strategies of the above mentioned conditions in our hospital setting. 
 
 
Genderwise distribution of treatment resistant schizophrenia was assessed here. The 
results of the study evince that distribution in males were 52 % and in females were 48 
 
% out of the 25 patients showing a small male predominance over female.  Uriel 
 
Heresco-Levy et al 
[27]
 study reveals a same level of gender distribution in treatment 
resistant schizophrenic patients. Genderwise distribution of treatment resistant 
depression was also studied. There was 44.4% of males and 55.6 % females out of the 
total 27 patients who enrolled in the study. Here there was a female predominance over 
males. Yiru Fang et al 
[28]
 showed a 54% female supremacy in their study. 
 
 
 
Through the study, it was perceived that mean age of treatment resistant schizophrenia 
to be =37.12 ± 7.79 years (Range: 26-57). Age category was ≤ 25=0%, 26 to 30=24%, 
31 to 35=20%, 36 to 40=28%, 41 – 45 =16% and above 45 =12%. Antonio T Lopes et 
al 
[29]
 in their study showed a mean age of 43 ± 12 years (Range: 24-72) for treatment 
resistant schizophrenia. For treatment resistant depression, the mean age was = 49 ± 
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10.7 yrs., (Range- 31 to 65 yrs.). The age category was ≤ 30=0%, 31 to 35=7.4% (n=2), 
36 to 40=18.5% (n=5), 41 to 45=14.8% (n=4) and above 45=59.3% (n=16). Yiru Fang 
et al 
[28]
 showed a mean age of 40.5 ± 11.5 years in their study for treatment resistant 
depression. 
 
 
 
Marital status of the patients were evaluated. We found out that in treatment resistant 
schizophrenia out of 25 patients, 15 patients were married (60%), 5 patients were single 
(20%) and 5 patients were divorcee (20%). Uriel Heresco-Levy et al 
[30]
 study showed 
73.4% patients (n=22) who are single which is contradictory to our study findings. 
Marital status of treatment resistant depression was also evaluated. Of the total 27 
patients, 25 patients (92.6) were married and 2 patients (7.4%) were single. Yiru Fang 
et al 
[28]
 study shows a 70% patients who were married. 
 
 
 
The evaluation of educational status in treatment resistant schizophrenia was made in 
the study. About 52.0% (n=13) had an education ≤SSLC, about 36% (n=9) had an 
education of plus two and about 12% (n= 3) had an education of degree or above out of 
the total sample in TRS. Most of the patients had an educational level of SSLC or less. 
Theresa Wimberley et al 
[31]
 in their study suggested the primary education level as 
88% in treatment resistant schizophrenic patients. For treatment resistant depression, 
about 66.7% (n=18) had an education ≤SSLC, about 18.5% (n=5) had an education of 
plus two and about 14.8% (n=4) had an education of degree or above. Here also more 
patients had an educational qualification of SSLC or below. But the result was 
conflicting to the result of M A Kenny et al 
[32]
 study which suggest that 60% of 
patients had an educational qualification of degree or above. 
 
 
 
 
Family history of any psychiatric conditions in patients with treatment resistant 
schizophrenia was assessed and out of the total 25 patients, about 72% (n=18) had a 
family history of any psychiatric conditions and 28% (n=7) had no family history. 
Uriel Heresco-Levy et al 
[30]
 showed a family history of mental illness in about 60% of 
the total patients. In treatment resistant depression, out of the total 27 patients, about 
74.1% (n=20) had a family history of any psychiatric conditions and 25.9% (n=7) had 
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no family history. Yiru Fang et al 
[28]
 in their study showed a family history of any 
psychiatric illness was 100% in patients with treatment resistant depression. 
 
Management of treatment resistant schizophrenia usually depends on the patient 
condition and the knowledge of treating physician. In our study, clozapine was found 
to be the widely used drug in our hospital setting (100%). All the patients who had 
TRS was treated with clozapine with different doses and showed improvement in 
PANSS scores. R. K. Solanki et al 
[33]
 suggest that clozapine emerges to be the gold 
standard in TRS patients. The most consisting results regarding efficacy in their study 
group had been observed with clozapine. The data from studies showed superior effects 
of clozapine on positive and negative symptoms, compared to prior treatment with 
typical neuroleptics. 
 
 
Clozapine + amisulpride combination was used in 20% of the patients and was the 
mostly used combination. The patients also showed improvement in their PANSS score 
after the treatment. A case series by Zink et al 
[34]
 showed improvement in previously 
treatment resistant symptoms following a combined treatment strategy of clozapine and 
amisulpride. Rob Kerwin et al 
[26]
 performed an open trial of amisulpride augmentation 
in a long term (52 weeks) study. Significant improvement was observed in most of the 
patients with no additional side effects. Clozapine + aripiprazole combination was used 
in 16% of the patients with TRS and an improvement in the psychotic symptoms were 
observed in them. Nilufar Mossaheb et al 
[35]
, in their study showed that using 
aripiprazole augmentation in treatment resistant schizophrenia with clozapine 
effectively reduced the symptoms in most of the patients. 
 
 
Augmentation therapy of clozapine with other antipsychotics such as risperidone, 
olanzapine, haloperidol and iloperidone were given for many patients with TRS and 
showed significant improvement in their symptoms. R K Solanki et al 
[33]
 showed the 
effectiveness of using first generation and second generation antipsychotics in 
combination with clozapine in their study. Miranda Chakos et al 
[36]
 revealed the 
results of a meta-analysis indicating that clozapine augmentation with atypical and 
typical antipsychotics improve the symptoms of treatment resistant schizophrenia in 
majority of the studied cases. Electro convulsive therapy was given as augmentation 
with clozapine and other antipsychotics in many patients (20%) and shown 
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improvement in their symptoms. Levy-Rueff et al 
[37]
 in their study implicated the 
improvement in symptoms when ECT was given along with antipsychotics. 
 
 
Treatment resistant depression was also managed with augmentation strategies in our 
hospital setting. Sertraline + venlafaxine + sodium valproate combination was majorly 
used in treating TRD patients (22.2%). Vieta E et al 
[38]
 in their research study 
suggested the effectiveness of using sertraline along with venlafaxine and sodium 
valproate in treatment resistant depression and their lower incidence of side effects. 
Martin Lopez et al 
[39]
 also established the effectiveness of using the above 
combination in TRD patients in their study. Venlafaxine was the drug used in majority 
(85.19%) of the TRD patients and it improved the symptoms in them. There were 
reduction in the MADRS score showing their improvement. Nierenburg et al 
[40]
 
reported an improvement in response rate of 40% in patients treated with venlafaxine 
who had failed a minimum of three adequate antidepressant trials. 
 
 
Lithium was also used in many patients (40.7%) as an augmentation therapy with other 
antidepressants. It also helped to improve the MADRS score in TRD patients. Fava M 
et al 
[41]
 in the well-studied and most established meta-analysis found 52% response 
rate in lithium treated TRD patients showing its use as an augmentation therapy in 
these patients. Sertraline (55.6%) and escitalopram (51.8%) were also used in the 
management of TRD in the hospital. Khalid Saad Al-Harbi 
[11]
 in his meta-analysis 
explained the use of sertraline and escitalopram along with venlafaxine and lithium in 
the management of symptoms in TRD patients. Use of sertraline and escitalopram 
improved the MADRS score in the treated patients. 
 
 
Bupropion, mirtazapine, sodium valproate and amitriptyline were also used as 
augmentation with venlafaxine and SSRIs in many patients. The combined use of these 
drugs improved the mental condition in most patients. Bodkin JA et al 
[42]
 examined 
combining bupropion and an SSRI or bupropion and venlafaxine and the response rate 
were more than 75% in the study. Carpenter LL et al 
[43]
 in an open labelled study in 
TRD patients, mirtazapine showed a response rate of 55% in nonresponders to standard 
antidepressants. Coraddo Barbui et al 
[44]
 in a systematic review of various RCTs of 
amitriptyline and SSRIs showed a 2.5% difference in the proportion of responders in 
favor of amitriptyline. ECT was also given in 11.1% of the TRD patients along with 
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other augmentation therapies. There were significant control over symptoms in most of 
the patients. Thase ME et al 
[45]
 in their study reported a response rate of 50% to 89% 
in patients who failed to respond to a single antidepressant. 
 
Initial PANSS score represents the severity of symptoms in treatment resistant 
schizophrenia before the treatment and final PANSS score represents the symptoms 
severity after treatment. In this study, initial PANSS score had a mean of 107.64 ± 
30.89 and final PANSS score had a mean of 83.96 ± 25.33. The mean difference was 
 
23.68. Wilcoxon Signed Ranks Test was used to test the significance and the study was 
significant with Z=4.378 and p=0.001 at 1% level of significance. The significance of 
the PANSS score difference suggested the effectiveness of treatment given. Large scale 
studies shows the significant reduction in TRS symptoms and effectiveness of 
treatment when PANSS initial and final scores differ significantly. 
 
 
 
 
Initial MADRS score represents the severity of symptoms in treatment resistant 
depression before the treatment and final MADRS score represents the symptoms 
severity after treatment. Here initial MADRS score had a mean of 40.11 ± 6.16 and 
final MADRS score had a mean of 24.85 ± 3.32. The mean difference was 15.26. 
Wilcoxon Signed Ranks Test was used to test the significance and the study was 
significant with Z=4.557 and p=0.001 at 1% level of significance. The significance of 
the MADRS score difference suggested the effectiveness of treatment given. Large 
scale studies shows the significant reduction in TRD symptoms and effectiveness of 
treatment when MADRS initial and final scores differ significantly. 
 
The adverse drug reactions that occurred in the patients during the study were 
evaluated and causality assessment were done using Naranjos scale. Out of the 25 
patients, 40% had an ADR of weight gain (n=10), 16% had the incidence of 
constipation (n=4), 12% had the episodes of EPS (n=3), 12% had incidence of DM 
(n=3), 8 had an ADR of sexual dysfunction (n=2) and 4% had tachycardia (n=1) during 
the study period. Krakowski M et al 
[46]
 in their study showed the incidence of weight 
gain and increased glucose level in patients who were taking clozapine and other 
second generation antipsychotics. Nilufar Mossaheb et al 
[35]
 in their study on 
aripiprazole established the occurrence of side effects like EPS and constipation in the 
study subjects. J Bobes et al 
[47]
 studied the frequency of sexual dysfunction in patients 
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using risperidone, olanzapine and haloperidol and found out high frequency of sexual 
dysfunction with these drugs. Kupchik et al 
[48]
 in their recent study about clozapine 
with ECT found out the occurrence of supraventricular and sinus tachycardia in some 
patients. When analysed on Naranjo ADR probability scale, majority of ADRs were 
rated as possible [n = 15 (65.22%)], followed by probable [n =8 (34.78%)]. 
 
Out of the total 27 TRD patients, 29.6% experienced an ADR of weight changes (n=8), 
18.52% experienced sexual dysfunction (n=5) and 22.22% experienced GI problems 
(n=6) during the study period. Yiru Fang et al 
[28]
 in their study about venlafaxine and 
mirtazapine shows the incidence of weight changes in patients with TRD as adverse 
drug effect. This study also gives evidences for the occurrence of GI disturbances in 
patients taking venlafaxine and mirtazapine. Montejo et al 
[49]
 reveals the incidence of 
sexual dysfunctions in patients taking venlafaxine, SSRIs etc in a prospective 
multicenter study. When analyzed on Naranjo ADR probability scale, majority of 
ADRs were rated as possible [n = 14 (73.68%)], followed by probable [n = 5 (26. 
32%)]. 
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7. CONCLUSION 
 
 
 
 
Treatment resistance in psychiatric patients is the major clinical challenge faced 
globally. Treatment resistance is generally defined as inadequate responses to a 
succession of treatments. The observations of the current study demonstrated the 
demographic profile and management strategies of treatment resistant schizophrenia 
and treatment resistant depression. An astronomical degree of treatment resistance was 
shown by many patients in the psychiatric department of our hospital. 
 
 
TRS and TRD are the major clinical challenges faced by the psychiatrists in the aspect 
of pharmacological management of these disorders. The major approach lies in 
providing a greater impact on quality of life of these patients. This study focused on the 
therapeutic options in case of treatment resistance which is clinically significant. Thus 
the study offered greater benefit to these patients by optimizing the treatment strategy 
and proper monitoring of adverse drug event of the drug. Moreover no study had been 
conducted so far in this area in the topic chosen in the particular demographic group. 
Therefore this study was conducted in these patients with treatment resistant 
schizophrenia and treatment resistant depression in a tertiary care referral hospital 
 
 
From the evaluation of the demographic profile, it concluded that the gender doesn‟t 
have much influence on the occurrence of TRS. But in cases of TRD, females had 
predominance over males. Furthermore family history had a strong correlation with the 
occurrence of both TRD and TRS. 
 
 
In some cases it was impossible to control the symptoms of both TRS and TRD and it 
is the biggest issue faced by physicians treating patients who were resistant to therapy. 
In psychiatric department of the hospital, clozapine is widely used to treat TRS patients 
in different doses along with other antipsychotic drugs. After the course of therapy, the 
patient‟s PANSS scores shown improvement. TRD, a complex clinical problem caused 
by multiple risk factors, was targeted by integrated therapeutic strategies which include 
optimization of medications, a combination of anti-depressants, switching of anti- 
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depressants, and an augmentation with non-antidepressants, psychosocial and cultural 
therapies and somatic therapies including ECT etc. 
 
 
Sertraline, Venlafaxine and Sodium valproate combination was majorly used in the 
treatment of TRD patients. Among them, Venlafaxine was used commonly in TRD. 
And the MADRS scores shown improvement in patient condition. Apart from drug 
therapy ECT when given in combination with antipsychotics were also effective in 
both TRS and TRD. 
 
 
Any unintended or noxious reaction up on the intake of the drug can be termed as 
adverse drug reactions. Psychiatric drugs are known to cause many adverse effects 
such as extra pyramidal symptoms, metabolic syndrome, hormonal issues etc. In this 
study the major ADRs shown by TRS patients include weight gain, constipation, 
diabetes mellitus, extra pyramidal symptoms, sexual dysfunction and tachycardia and 
those of TRD patients include weight changes, GI problems and sexual dysfunction. 
 
 
During the study, many challenges and limitations were faced due to its complexity in 
its nature. Ethical issues, fluctuations in illness, study patients run the risk of worsening 
of illness and suicide risk as well as the non-adherence to treatment and not appearing 
on OPD regularly for follow up. Rating scales are essential for assessment of drug 
response, but those were not suitable for all patients especially those with a poor 
socioeconomic status. 
 
 
In summary, TRS in this specific population unresponsive to previous treatment, a 
combination of clozapine with aripiprazole, as well as other augmentation strategies for 
clozapine, seen worthy of further exploration. However, given the lack of clear cut 
evidence for an advantage of antipsychotic poly pharmacy in general, no confident 
recommendations can be made and careful clinical appraisal of the risk benefit ratio of 
all options is warranted. 
 
 
TRD continued to challenge mental health care providers and further relevant research 
involving newer drugs is warranted to improve the quality of life of patients with the 
disorder. And some groups of patient needs further study to identify the most effective 
therapeutic modalities. Newer biomarker based anti-depressants and other drugs 
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together with non-drug strategies, are on the horizon to address further the multiple 
complex issues of treatment resistant depression. 
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